TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05181527
Drug: Selective Serotonin Reuptake Inhibitors
Normalized name: Selective serotonin reuptake inhibitors
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in both the study arms will receive SSRI for 8 weeks.
Study: NCT05181527
Drug: Dextromethorphan
Normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients in the test group will get Dextromethorphan 30 mg once daily orally as an add-on to ongoing SSRI treatment for 8 weeks.
Study: NCT06191094
Drug: Faricimab Injection
Normalized name: faricimab Injection
DrugBank: Faricimab (DB15303)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pre-operative injection of bevacizumab appears to have mixed results in lowering post-operative vitreous hemorrhage. One potential reason is due to aspiration and removal of medication in the vitreous humor at the time of pars plana vitrectomy leading to less than anticipated results in controlling neovascularization and vitreous hemorrhage post-operatively. To avoid attenuation of our desired effect we plan to repeat faricimab injection post-operatively around week one.
Study: NCT04766450
Drug: Acetyl cysteine
Normalized name: Acetyl cysteine
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NAC exhibits potent anti-oxidant activity in the cell through augmentation of intracellular GSH, which is a major component of the pathways by which cells are protected from OTS, and its direct scavenging activity of free radicals by providing sulfhydryl groups. Additionally, NAC treatment exhibits anti-inﬂammatory effects via inhibition of NF-κB activation and reducing subsequent cytokine production . Mitochondria-protective mechanisms of NAC may also be related to its anti-oxidant and anti-inﬂammatory properties
Study: NCT04186741
Drug: Hyperbaric oxygen
DrugBank: Oxygen (DB09140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients already on treatment by hyperbaric oxygen therapy for medical conditions requiring treatment by it
Study: NCT05290025
Drug: Nicotine patch
Normalized name: Nicotine Patch
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: \> 20 cigarettes per day: 21 mg nicotine/ 24 hours 10-20 cigarettes per day: 14 mg nicotine/ 24 hours 5-10 cigarettes per day: 7 mg nicotine/ 24 hours
Study: NCT05290025
Drug: Nicotine gum
Normalized name: Equate Nicotine Gum 4mg Starter Kit
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine chewing gum will be available in 1 and 2 mg strengths. Patients may individually choose which strength to use. Maximum 12 chewing gums per day
Study: NCT05290025
Drug: Nicotine lozenge
Normalized name: nicotine Lozenge Product
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine lozenges will be available in 1 and 2 mg strengths. Patients may individually choose which strength to use. Maximum 12 lozenges per day
Study: NCT04417894
Drug: dupilumab
Normalized name: Dupilumab
DrugBank: Dupilumab (DB12159)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Solution for subcutaneous (SC) injection administration
Study: NCT03792295
Drug: Oxycodone
Normalized name: Oxycodone
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Classic opiod pain treatment group
Study: NCT04737655
Drug: TRIMBOW® pressurised inhalation solution: Beclometasone dipropionate / formoterol fumarate /glycopyrronium 87/5/9 µg per inhalation
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Evaluate Trimbow associated with the standard of care in comparison with the standard of care alone.
Study: NCT05880342
Drug: Reboxetine Pill
Normalized name: reboxetine Pill
DrugBank: Reboxetine (DB00234)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg
Study: NCT05880342
Drug: Methylphenidate Oral Product
Normalized name: methylphenidate Oral Product
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 mg
Study: NCT05746104
Drug: Administration of Indocyanine Green (ICG) and Visualization of Tumor
Normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: A single dose of the study drug, ICG, of less than 2 mg/kg will be administered on the day of surgery. The visualization of second window ICG for tumor will be performed approximately one to four hours after administration, depending on how long it takes for the neurosurgeon to get through the skin/skull or lamina/dura to the tumor.
Study: NCT06035250
Drug: Neoadjuvant Chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants in this group are diagnosed with gastric cancer and are scheduled to undergo neoadjuvant chemotherapy as a part of their treatment regimen. The specific chemotherapy drugs, dosages, and schedules will be determined according to established clinical guidelines and the participant's specific condition.
Study: NCT06554717
Drug: Tesamorelin
Normalized name: Tesamorelin
DrugBank: Tesamorelin (DB08869)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tesamorelin SV 1.4 mg given subcutaneously daily
Study: NCT06242145
Drug: Clopidogrel tablet
Normalized name: Clopidogrel Tablets
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Efficacy and safety of a 300mg loading dose of ticagrelor administered within 24 hours of first-ever ischemic stroke followed by 75mg daily for 3 months will be assessed through NIHSS, mRS, duration of hospital stay, new ischemic stroke, and possible adverse effects.
Study: NCT06242145
Drug: Cilostazol 100 MG
Normalized name: cilostazol 100 MG
DrugBank: Cilostazol (DB01166)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Efficacy and safety of 200 mg clopidogrel followed by 100 mg twice daily for 3 months will be assessed through NIHSS, mRS, duration of hospital stay, new ischemic stroke, and possible adverse effects.
Study: NCT04830462
Drug: Isoniazid 300 Mg ORAL TABLET
Normalized name: ISONIAZID 300 mg ORAL TABLET
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoniazid 300 mg daily for 6 months
Study: NCT06450145
Drug: interferon α-2b
Normalized name: Interferon α-2b
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eligible APL patients with arsenic-resistant relapse will enter the run-in period, and the subjects in the run-in phase will be treated with arsenic combined with venetoclax. After the run-in period, the patients were treated with interferon α-2b, arsenic trioxide for injection and venetoclax until the outcome of CR/PR/PD/ death/withdrawal/loss to follow-up occurred. Tumor assessments were performed every 4 to 6 weeks (as determined by the investigator) during trial treatment. Those who achieved CR/PR/PD/ withdrawal were then returned to standard treatment (treatment regimen was determined by the clinician), and those who completed the combination treatment period of the trial entered the survival follow-up period.
Study: NCT05506956
Drug: Flotetuzumab
Normalized name: Flotetuzumab
DrugBank: Flotetuzumab (DB15223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients enrolled on dose level 1 (DL1) will receive flotetuzumab by continuous infusion using multi-step lead-in dosing, and then 500 ng/kg/day on days 7-28. After one cycle, all patients will undergo a bone marrow biopsy to assess response including assessment of minimal residual disease (MRD). Patients who fail to achieve a CR, CRi, CRh (complete remission with partial hematologic recovery), or MLFS may continue with subsequent induction cycles as a continuous infusion up to a total of five cycles. If there is evidence of response (CR, CRi, CRh, or MLFS) and the toxicities of treatment are acceptable, patients will be eligible for two consolidation cycles. Additional bone marrow biopsies for response assessment will be performed after the second cycle. If there is a need to de-escalate dosing based on toxicity, then patients will be enrolled on DL-1 using multi-step lead-in dosing, and then 300 ng/kg/day on days 5-28 of the first cycle and days 1-28 of subsequent cycles.
Study: NCT06784349
Drug: ALN-APOC3
Normalized name: ALN-AT3SC
DrugBank: Fitusiran (DB15002)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as per the protocol
Study: NCT04741477
Drug: CBD
Normalized name: CBD
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: CBD will be topically applied
Study: NCT04741477
Drug: THC
Normalized name: THC
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: THC will be topically applied
Study: NCT04718025
Drug: Ticagrelor 90mg
Normalized name: TICAGRELOR 90MG TAB
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Up to day 30 after ACS, all enrolled patients will receive standard-dose ticagrelor 2x90mg as a part of dual antiplatelet therapy. Participants in SDTA arm will continue treatment with ticagrelor 2x90mg until 12 months post-ACS, while patients in LDTA and LDTP will be switched to low-dose ticagrelor 2x60 mg starting on day 31.
Study: NCT06519786
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients will receive metformin immediate-release tablets orally for 24 weeks. Starting dose will be 500 mg once daily for all patients and the dose will be increased by 500 mg weekly until the goal dose is achieved (500 mg twice daily for patients \< 10 years of age, and 1000 mg twice daily for patients 10 years or older)
Study: NCT04718025
Drug: Ticagrelor 60mg
Normalized name: TICAGRELOR 60MG TAB
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Starting from day 31, LDTA and LDTP patients will receive low-dose ticagrelor 2x60mg until 12 months post-ACS.
Study: NCT04718025
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Up to day 90 after ACS, all enrolled patients will receive aspirin 1x100mg as a part of dual antiplatelet therapy. Starting from day 91, LDTP patients will discontinue aspirin and proceed with low-dose ticagrelor monotherapy until 12 months post-ACS, while patients in LDTA and SDTA will continue aspirin 1x100 mg until 12 months post-ACS.
Study: NCT06367881
Drug: Alveofact
Normalized name: Alveofact
DrugBank: Calfactant (DB06415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intratracheal High-dose Alveofact versus Low-dose Alveofact with or without Budesonide
Study: NCT06367881
Drug: Budesonide
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide
Study: NCT05495893
Drug: Mycophenolate Mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The patients will be divided into two groups randomly. Mycophenolate mofetil, tablets, 30-40mg/ (kg · day), BID, the maximum amount is no more than 2g/d. Steroids : intravenous methylprednisolone, 15\~30mg/kg · day, maximum 1000mg/day, 3 consecutive days a week for 2 weeks; during the interval of methylprednisolone pulse therapy and after:prednisone tablets 2mg/kg · day with a maximum dose 60mg / day. The duration of induction therapy: 6 months.
Study: NCT05236998
Drug: Dapagliflozin and Sitagliptin
Normalized name: saxagliptin and dapagliflozin
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Single oral administration of Dapagliflozin and Sitagliptin after an overnight fast
Study: NCT05549115
Drug: levofloxacin-sensitive(rescue treatment)
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: esomeprazole (20 mg, twice daily), levofloxacin (500 mg, once daily), amoxicillin (1.0 g, twice daily), and colloidal bismuth pectin (150 mg, four times daily) for 14 days
Study: NCT05549115
Drug: levofloxacin-resistant(rescue treatment)
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: esomeprazole (20 mg, twice daily), furazolidone (100 mg, twice daily), amoxicillin (1.0 g, twice daily), and colloidal bismuth pectin (150 mg, four times daily) for 14 days
Study: NCT05549115
Drug: empirical therapy group rescue treatment
Normalized name: colloidal oatmeal
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: esomeprazole (20 mg, four times daily) and amoxicillin (750 mg, four times daily) for 14 days
Study: NCT06374901
Drug: Tislelizumab
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative treatment with Tislelizumab
Study: NCT04760626
Drug: Insulin icodec
Normalized name: insulin icodec
DrugBank: Insulin icodec (DB16693)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive subcutaneous (s.c.) injections of insulin icodec once weekly for 52 weeks.
Study: NCT06439849
Drug: S-Gboxin
Normalized name: S-2
DrugBank: Racepinephrine (DB11124)
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-Gboxin (lyophilized form of S-Gboxin) for the treatment diffuse midline glioma with H3 K27M / H3 K28M mutation
Study: NCT05813951
Drug: Linezolid
Normalized name: Linezolid
DrugBank: Linezolid (DB00601)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: linezolid either continues infusion or standard intermittent dose
Study: NCT04910425
Drug: Fluorine F 18 DCFPyL
Normalized name: DCFPyL F-18
DrugBank: Piflufolastat F 18 (DB14805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT04910425
Drug: Gadobenate Dimeglumine
Normalized name: Gadobenate Dimeglumine
DrugBank: Meglumine (DB09415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT04910425
Drug: Gadobutrol
Normalized name: Gadobutrol
DrugBank: Gadobutrol (DB06703)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT04760626
Drug: Insulin Glargine 100U/mL
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive subcutaneous (s.c.) injections of insulin analogues once daily for 52 weeks.
Study: NCT04760626
Drug: Insulin Degludec
Normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive subcutaneous (s.c.) injections of insulin analogues once daily for 52 weeks.
Study: NCT06501651
Drug: Sacubitril/Valsartan
Normalized name: SACUBITRIL/VALSARTAN
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sacubitril/Valsartan is a novel antihypertensive medication composed of an angiotensin II receptor blocker (ARB) Valsartan and a neprilysin inhibitor Sacubitril in a 1:1 molar co-crystal form. Sacubitril is a prodrug that, once ingested, is metabolized by esterases into its active form, which inhibits neprilysin activity. Neprilysin has various substrates, including natriuretic peptides and angiotensin II (Ang II). By inhibiting neprilysin, the levels of natriuretic peptides that have antihypertensive and organ-protective effects are increased. The other component, Valsartan, effectively inhibits the Ang II type 1 receptor (AT1R), providing additional antihypertensive and organ-protective effects. The co-crystal structure ensures that Sacubitril and Valsartan have similar absorption and elimination rates, thereby synchronizing their pharmacological effects.
Study: NCT06501651
Drug: Valsartan
Normalized name: Valsartan
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Valsartan, effectively inhibits the Ang II type 1 receptor (AT1R), providing both antihypertensive and organ-protective effects.
Study: NCT06244758
Drug: Finerenone 20 MG Oral Tablet
Normalized name: finerenone 20 MG Oral Tablet
DrugBank: Finerenone (DB16165)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The intervention is administered orally.
Study: NCT04760626
Drug: Insulin Glargine 300U/mL
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive subcutaneous (s.c.) injections of insulin analogues once daily for 52 weeks.
Study: NCT05742594
Drug: Lazertinib
Normalized name: Lazertinib
DrugBank: Lazertinib (DB16216)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lazertinib will be administered orally.
Study: NCT06220097
Drug: Mitoxantrone hydrochloride liposome Injection-based bridging therapy+ Fludarabine-based chemotherapy +CD19 CAR-T Cells
Normalized name: Anti-BCMA CAR T cell
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bridging therapies from enrollment before CD19 CAR-T infusion. A treatment regimen containing mitoxantrone hydrochloride liposome injection, including but not limited to the following recommended regimens: R-MINE regimen (rituximab + ifosfamide + mitoxantrone hydrochloride liposome + etoposide) G-MINE regimen (obinutuzumab + ifosfamide + mitoxantrone hydrochloride liposome + etoposide) MAE regimen (mitoxantrone liposome hydrochloride + cytarabine + etoposide) . The recommended dose of mitoxantrone liposome hydrochloride is not limited. For patients who achieve SD or better after one cycle of bridging treatment, it is up to the investigator to decide whether to receive CAR-T therapy. Fludarabine-based lymphodepletion chemotherapy was followed by CD19 CAR-T cells (relma-cel, axi-cel or humanized CAR19). Relma-cel and axi-cel will be infused according to the instructions. CART19 infusion is conducted at a dose of 1x10\^6/kg on day 0 and day 1 respectively.
Study: NCT04801082
Drug: Alcohol injection
Normalized name: Dehydrated Alcohol Injection Solution
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chemical ablation is performed by injection of 10 mL of 0.25% bupivacaine, followed by 10 mL of 98% dehydrated alcohol using a 22G FNA needle (Cook and Olympus)
Study: NCT06063421
Drug: Nicotine Replacement Therapy
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NRT will be in the form of combination therapy with a transdermal nicotine patch (7, 14, or 21mg) and an oral product: either gum or lozenge in 1, 2, or 4mg strength.
Study: NCT04683965
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pemetrexed 500 mg/m2 d1
Study: NCT04683965
Drug: TAS-102
Normalized name: TAS-102
DrugBank: TAS-102 (DB08937)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAS-102, capsule, 35mg/m2, bid,p.o, d1\~5,d8\~12
Study: NCT04683965
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab 5 mg/kg d1,d14
Study: NCT06282874
Drug: Lorlatinib
Normalized name: LORLATINIB
DrugBank: Lorlatinib (DB12130)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lorlatinib 100 mg once daily on days 1 to 28 of each 28-day cycle
Study: NCT06410612
Drug: regional anesthesia and PAI
Normalized name: cytarabine and daunorubicin
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: this is the block portion of the study
Study: NCT05367960
Drug: Zatolmilast/ BPN14770
DrugBank: Zatolmilast (DB14790)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25mg zatolmilast/BPN14770 (Adults) or 15 mg zatolmilast/BPN14770 (Adolescents \<43 kg)
Study: NCT06301178
Drug: Cholecalciferol
Normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D has various critical regulatory roles, including inflammatory control, cellular proliferation and differentiation, and wound healing regulation.
Study: NCT06447662
Drug: PF-07934040
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: panKRAS inhibitor
Study: NCT00380822
Drug: miglitol
Normalized name: Miglitol
DrugBank: Miglitol (DB00491)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05603715
Drug: Pyridostigmine Bromide
Normalized name: Pyridostigmine Bromide
DrugBank: Pyridostigmine (DB00545)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose escalation trial of Pyridostigmine bromide oral tablets 60-180 mg TID for four weeks
Study: NCT05452785
Drug: DFD-29 (Minocycline) Fasting
Normalized name: Fast Freeze
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In each study period, a single 40 mg dose of DFD-29 Capsules will be administered orally with approximately 240 mL of water, in the morning, following a 10-hour overnight fast.
Study: NCT05452785
Drug: Solodyn (Minocycline) Fasting
Normalized name: Solodyn
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In each study period, a single 105 mg dose of SOLODYN® Tablets will be administered orally with approximately 240 mL of water, in the morning, following a 10-hour overnight fast.
Study: NCT03129490
Drug: Dabigatran Etexilate Oral Capsule
Normalized name: dabigatran etexilate Oral Capsule
DrugBank: Dabigatran etexilate (DB06695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After cluster randomization, the cluster will use dabigatran to all their patients with non-valvular atrial fibrillation when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time. It is the clusters and not the patient that are randomized.
Study: NCT03129490
Drug: Rivaroxaban Oral Tablet
Normalized name: rivaroxaban Oral Tablet
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: After cluster randomization, the cluster will use rivaroxaban to all their patients with non-valvular atrial fibrillation when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time. It is the clusters and not the patient that are randomized.
Study: NCT03129490
Drug: Edoxaban Oral Tablet
Normalized name: edoxaban Oral Tablet
DrugBank: Edoxaban (DB09075)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: After cluster randomization, the cluster will use edoxaban to all their patients with non-valvular atrial fibrillation when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time. It is the clusters and not the patient that are randomized.
Study: NCT03129490
Drug: Apixaban Oral Tablet
Normalized name: apixaban Oral Tablet
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: After cluster randomization, the cluster will use apixaban to all their patients with non-valvular atrial fibrillation when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time. It is the clusters and not the patient that are randomized.
Study: NCT06146972
Drug: Iguratimod
Normalized name: Iguratimod
DrugBank: Iguratimod (DB12233)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Iguratimod 25mg bid + tofacitinib 5mg bid
Study: NCT05066217
Drug: Clemizole HCl
Normalized name: clemizole HCl
DrugBank: Clemizole (DB15932)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-Blind Randomized
Study: NCT05859477
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 360 mg, i.v., every 3 weeks
Study: NCT05859477
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 130 mg/m², i.v., day 1, every 3 weeks
Study: NCT05067270
Drug: Sodium Citrate
Normalized name: Sodium Citrate
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered SC infusion.